The rationale, design, definitions of outcomes, and main results of the AVERROES trial (ClinicalTrials.gov No. NCT00496769) have been published. 2 In summary, this was a randomized, multicenter, doubleblinded, parallel-group trial which compared apixaban (at a dose of 5 mg twice daily, with a dose adjustment to 2.5 mg BID for selected patients) with aspirin (81-324 mg per day) for the prevention of Background and Purpose-The main objective of the present analysis was to assess the effect of treatment with aspirin compared with apixaban on ischemic stroke and major bleeding in women compared with men. Female patients with atrial fibrillation are at increased stroke risk compared with male patients, and the underlying reasons for higher risk are uncertain.
T he impact of sex on stroke risk in patients with atrial fibrillation (AF) is best tested in nonanticoagulated subjects (usually treated with aspirin), in contrast to other trial subanalyses, where most patients are anticoagulated. 1 AVERROES (Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment) was a randomized, multicenter, parallel-group trial which compared apixaban with aspirin for the prevention of stroke and systemic embolism in patients with nonvalvular-persistent paroxysmal or permanent AF at moderate-high risk of stroke deemed unsuitable for treatment with a vitamin K antagonist. 2 This post hoc ancillary analysis of the AVERROES trial offers an opportunity to evaluate sex-related differences in stroke, as well as efficacy and safety of non-vitamin K oral anticoagulants in comparison to aspirin.
The principal objective of the present analysis was to assess the effect of treatment with aspirin or apixaban on ischemic stroke, in relation to sex. As a secondary analysis, we identified risk factors for stroke in the data set of the AVERROES trial among aspirin-and apixaban-treated patients.
Stroke
July 2014 stroke and systemic embolism in patients with nonvalvular-persistent paroxysmal or permanent AF at moderate-high risk of stroke who had declined, failed anticoagulation use or for whom anticoagulation was deemed unsuitable. The mean follow-up period was 1.1 years. Analyses were conducted according to the intention-to-treat principle. The outcome events were censored either at study closure or loss to follow-up or death. Baseline characteristics of male and female patients were compared using 2-sample Wilcoxon tests for continuous variables and Pearson χ 2 tests for categorical variables. Hazard ratios for the effect of apixaban versus aspirin were estimated using Cox proportional hazards regression models in male and female populations. Interactions between the treatment effect and sex were tested in the Cox models fitted to all patients. Univariate and multivariable Cox models were used to investigate the impact of individual risk factors on the risk of ischemic stroke. We calculated the absolute risk reduction and number needed to treat using the Kaplan-Meier estimates of 1-year survival. 3 Analyses were conducted using SAS software, version 9.2. All tests of statistical significance were 2 sided. Significance was declared at the 5% level.
Results
Female patients in both treatment groups tended to be older than male patients (Table) . Women had less peripheral artery disease and more heart failure in both aspirin-and apixaban-treated patients. Mean CHADS 2 (congestive heart failure, hypertension, age of 75 years or older, diabetes [1 point each], stroke or transient ischemic attack [2 points]) score was similar between male and female patients. Mean CHA 2 DS 2 -VASc score (cardiac failure or dysfunction, hypertension, age ≥75[doubled], diabetes, stroke[doubled]-vascular disease, age 65-74 and sex category [female]) score was higher in women (as female sex added 1 point to this score; Table I in the online-only Data Supplement).
Female patients had higher annual ischemic stroke rates in both aspirin and apixaban treatment groups, when compared with male patients (Table) . The efficacy of apixaban compared with aspirin for stroke reduction was consistent in both men and women (P int =0.84; Figure) . Female and male patients had comparable annual major bleeding and intracranial bleeding rates in both aspirin and apixaban treatment groups (P int =0.97; Table II in the online-only Data Supplement).
In univariate analysis ( Table II in the online-only Data Supplement), significant predictors for stroke in female patients were age ≥75 years (P<0.001) and prior stroke or transient ischemic attack (P=0.002). In multivariable analysis of aspirin-treated patients, only estimated glomerular filtration rate <60 mL/min (P=0.008) was an independent predictor of ischemic stroke in male patients ( Table III in the online-only Data Supplement), whereas among female patients, age ≥75 years (P=0.004) and prior stroke or transient ischemic attack (P=0.01) were significant predictors. No independent predictors of ischemic stroke were evident in apixaban-treated patients, in either male or female subgroups.
In the whole cohort of aspirin-treated patients, independent predictors of ischemic stroke in the aspirin-treated patients were age ≥75 years, high body mass index (>31 kg/m 2 ), peripheral artery disease, and subtype of AF, with a trend toward a higher risk in women (hazard ratio, 1.50; 95% confidence interval, 0.99-2.29; P=0.06). In apixaban-treated patients, no significant predictors were seen, with nonsignificant trends for hypertension (P=0.05) and female sex (P=0.09; Table III in the online-only Data Supplement).
For men, the number needed to treat (1-year risk) for apixaban (compared with aspirin) for the end point of ischemic stroke was 51 (95% confidence interval, 33-108), whereas for women, the number needed to treat was 52 (95% confidence interval, 30-194). In the whole cohort, number needed to treat was 51 (95% confidence interval, 36-90).
Discussion
In this post hoc analysis of a contemporary randomized clinical trial involving AF patients who were randomized to apixaban or aspirin, we found that female patients had higher ischemic stroke rates in both aspirin and apixaban treatment groups, compared with male patients, but the relative efficacy of apixaban over aspirin was consistent irrespective of sex. Second, female and male patients had comparable major bleeding rates in both aspirin and apixaban groups, and estimates of the relative effect of apixaban compared with aspirin were consistent in both sexes.
As shown in a recent systematic review, 4 women have been noted to have higher stroke rates compared with men, as previously observed in other studies, 5 even while on warfarin 1, 6 The mechanisms of increased stroke in females patients with AF have attracted much interest, 7 and quality of anticoagulation control, hormones, and renal dysfunction have all been proposed. Only estimated glomerular filtration rate <60 mL/min was an independent predictor of stroke in male patients taking aspirin. Renal impairment has been associated with a higher risk of stroke, death, myocardial infarction, and major bleeding in patients with AF. 8 In AVERROES (which excluded those with severe renal failure), the efficacy of apixaban is maintained irrespective of renal function, and the safety aspect (as reflected by major bleeding) was particularly marked in those with moderate renal impairment. 9 Of note, overall bleeding risk was similar in men and women with AF.
Conclusions
In this post hoc analysis of a contemporary randomized clinical trial with aspirin-treated patients, female patients with AF had higher ischemic stroke rates compared with male patients, which was related to age and prior stroke/transient ischemic attack. The superiority of apixaban compared with aspirin for stroke prevention was maintained with a similar benefit seen in both women and men. Major bleeding rates were not significantly different between aspirin-and apixaban-treated patients, whether male or female. † Due to missing values for some of the predictor variables, the total number of patients used in the multivariable analysis was 5584 (2784 in the aspirin group and 2800 in the apixaban group), and the number of events was 128 (first ischaemic stroke, 93 in the aspirin group, 35 in the apixaban group). ‡ P value is from the likelihood ratio test of the predictor overall significance in the multivariable Cox proportional hazards regression model. Hazard ratio 95% confidence interval limits are the profile likelihood limits. § Calculated using the CKD-EPI equation. 
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